1. Home
  2. EBF vs CABA Comparison

EBF vs CABA Comparison

Compare EBF & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ennis Inc.

EBF

Ennis Inc.

HOLD

Current Price

$21.49

Market Cap

519.5M

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.19

Market Cap

495.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EBF
CABA
Founded
1909
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
519.5M
495.7M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
EBF
CABA
Price
$21.49
$3.19
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$14.50
AVG Volume (30 Days)
160.1K
5.6M
Earning Date
04-20-2026
05-14-2026
Dividend Yield
4.85%
N/A
EPS Growth
7.79
10.26
EPS
0.39
N/A
Revenue
N/A
N/A
Revenue This Year
$2.96
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$55.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.30
$1.26
52 Week High
$22.36
$4.23

Technical Indicators

Market Signals
Indicator
EBF
CABA
Relative Strength Index (RSI) 57.03 51.38
Support Level $19.92 $3.12
Resistance Level $22.36 $3.34
Average True Range (ATR) 0.58 0.21
MACD 0.10 0.03
Stochastic Oscillator 77.72 82.35

Price Performance

Historical Comparison
EBF
CABA

About EBF Ennis Inc.

Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others. The company's single reportable segment : Print derives its operating revenues from the manufacturing of mostly custom or semi-custom printed products sold mostly to independent distributors in the United States.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Share on Social Networks: